|

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

RECRUITINGSponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Actively Recruiting
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano
Started2022-03-10
Est. completion2026-12-31
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05621837

Summary

The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria

* Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included
* Will and ability to comply with the protocol
* Willingness and ability to provide an adequate archival Formalin-Fixed Paraffin-Embedded (FFPE) tumor sample available for exploratory biomarker analysis
* Age from 18 to 90 years at the time of recruitment
* ECOG Performance Status \<= 2
* Understanding and signature of the informed consent
* Consenting to participate to the socio-economical-psychological survey

Exclusion Criteria

* Known history of HIV infection
* Serious neurological or psychiatric disorders
* Pregnancy or lactation
* Inability or unwillingness of participant to give written informed consent
* Inability or unwillingness to be regularly followed up at the same center

Conditions8

Breast CancerCancerMelanomaNSCLCRenal Cell CarcinomaSmall Cell CarcinomaSquamous Cell Carcinoma of Head and NeckUrinary Bladder Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.